Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. reported on February 6, 2024, that Dr. Shafique Virani has transitioned from his role as Chief Business Officer to become a Senior Strategic Advisor. In his new capacity, Dr. Virani will continue to support the company's business development and further its mission. Concurrently, Matthew Kinn, previously Senior Vice President of Business Development and Corporate Initiatives, has been promoted to the executive team, taking over the responsibilities of Dr. Virani. Mr. Kinn has been with Recursion since 2017 and has a background with the Boston Consulting Group. As part of the transition, Dr. Virani has entered into agreements with Recursion that include advisory fees, continued equity vesting, COBRA premium payments, and a potential lump sum payment should the agreement terminate early. The company plans to file these agreements as exhibits in a periodic report.
Recursion Pharmaceuticals, Inc. reported on February 6, 2024, that Dr. Shafique Virani has transitioned from his role as Chief Business Officer to become a Senior Strategic Advisor. In his new capacity, Dr. Virani will continue to support the company's business development and further its mission. Concurrently, Matthew Kinn, previously Senior Vice President of Business Development and Corporate Initiatives, has been promoted to the executive team, taking over the responsibilities of Dr. Virani. Mr. Kinn has been with Recursion since 2017 and has a background with the Boston Consulting Group. As part of the transition, Dr. Virani has entered into agreements with Recursion that include advisory fees, continued equity vesting, COBRA premium payments, and a potential lump sum payment should the agreement terminate early. The company plans to file these agreements as exhibits in a periodic report.
Recursion Pharmicals, Inc.于2024年2月6日报告称，沙菲克·维拉尼博士已从首席商务官的职位过渡到高级战略顾问。在新的职位上，维拉尼博士将继续支持公司的业务发展并推进其使命。同时，曾任业务发展和企业计划高级副总裁的马修·金恩已晋升为执行团队，接替维拉尼博士的职责。Kinn先生自2017年以来一直在Recursion工作，拥有波士顿咨询集团的背景。作为过渡的一部分，维拉尼博士已与Recursion签订了协议，其中包括咨询费、持续股权归属、COBRA保费支付以及协议提前终止后可能的一次性付款。该公司计划将这些协议作为证物提交定期报告。
Recursion Pharmicals, Inc.于2024年2月6日报告称，沙菲克·维拉尼博士已从首席商务官的职位过渡到高级战略顾问。在新的职位上，维拉尼博士将继续支持公司的业务发展并推进其使命。同时，曾任业务发展和企业计划高级副总裁的马修·金恩已晋升为执行团队，接替维拉尼博士的职责。Kinn先生自2017年以来一直在Recursion工作，拥有波士顿咨询集团的背景。作为过渡的一部分，维拉尼博士已与Recursion签订了协议，其中包括咨询费、持续股权归属、COBRA保费支付以及协议提前终止后可能的一次性付款。该公司计划将这些协议作为证物提交定期报告。
有用
没用